Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.53 |
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4543188 | 0.90 | HRH3 (0.55) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL10025769 | 0.89 | EBP (0.52) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL5713203 | 0.88 | ABCB1 (0.54) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL14619303 | 0.85 | HRH3 (0.50) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL20387890 | 0.84 | LTA4H (0.62) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL13082986 | 0.84 | LTA4H (0.59) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL113833 | 0.81 | EBP (0.73) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL8015672 | 0.81 | EBP (0.88) | EBPSIGMAR1HRH3LTA4HESR1 | |
| SCHEMBL4802603 | 0.80 | MPO (0.60) | ESR1MPOABCB1 | |
| SCHEMBL3785482 | 0.80 | MPO (0.55) | EBPSIGMAR1MPOABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937188-B2 | Process for the preparation of lasofoxifene tartrate | GLENMARK GENERICS LTD. (IN) | 2015-01-20 | — | — | US | claimed |
| EP-2424839-A2 | A PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | Glenmark Generics Limited (IN) | 2012-03-07 | — | — | EP | claimed |
| US-20120045648-A1 | PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | GLENMARK GENERRICS LTD (IN) | 2012-02-23 | — | — | US | claimed |
| WO-2010125578-A2 | A PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | GLENMARK GENERICS LIMITED (IN) | 2010-11-04 | — | — | WO | claimed |
| EP-1411049-A1 | Estrogen Agonists/Antagonists | PFIZER INC. (US) | 2004-04-21 | — | — | EP | claimed |
| US-6441193-B1 | INTERMEDIATES SUCH AS 1-(2-(4-(6-METHOXY-3,4-DIHYDRONAPHTHA-LEN-1-YL)PHENOXY)ETHYL)PYRROLIDINE AND COMPOUNDS SUCH AS CIS-6-PHENYL-5-(4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL)-5,6,7,8 -TETRAHYDRONAPHTHALEN-2-OL, HYDROBROMIDE SALT | PFIZER INC. | 2002-08-27 | — | — | US | claimed |
| EP-0802910-B1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER (US) | 2002-03-13 | — | — | EP | claimed |
| EP-1151998-A1 | Estrogen agonists/antagonists | PFIZER INC. (US) | 2001-11-07 | — | — | EP | claimed |
| EP-0802910-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER INC. (US) | 1997-10-29 | — | — | EP | claimed |
| WO-1996021656-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER, INC. (US) | 1996-07-18 | — | — | WO | claimed |
| US-8937188-B2 | Process for the preparation of lasofoxifene tartrate | GLENMARK GENERICS LTD. (IN) | 2015-01-20 | — | — | US | disclosed |
| US-8937188-B2 | Process for the preparation of lasofoxifene tartrate | GLENMARK GENERICS LTD. (IN) | 2015-01-20 | — | — | US | disclosed |
| US-8937188-B2 | Process for the preparation of lasofoxifene tartrate | GLENMARK GENERICS LTD. (IN) | 2015-01-20 | — | — | US | disclosed |
| WO-2012159981-A2 | PROCESS FOR THE PREPARATION OF α-SUBSTITUTED KETONES AND THEIR APPLICATION IN SYNTHESIS OF PHARMACEUTICALLY ACTIVE COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012159981-A2 | PROCESS FOR THE PREPARATION OF α-SUBSTITUTED KETONES AND THEIR APPLICATION IN SYNTHESIS OF PHARMACEUTICALLY ACTIVE COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2012-11-29 | — | — | WO | disclosed |
| EP-0876359-A1 | (-) CIS-6(S)-PHENYL-5(R) 4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]-5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL D-TARTRATE | PFIZER INC. (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0802910-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER INC. (US) | 1997-10-29 | — | — | EP | disclosed |
| WO-1997016434-A1 | (-) CIS-6(S)-PHENYL-5(R)[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]-5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL D-TARTRATE | PFIZER INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| US-5552412-A | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis | PFIZER INC (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1996021656-A1 | ESTROGEN AGONISTS/ANTAGONISTS | PFIZER, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045648-A1 | PROCESS FOR THE PREPARATION OF LASOFOXIFENE TARTRATE | CYP19A1, CYP51A1, CYP2F1 | EBP 1181/4885SIGMAR1 1272/4885HRH3 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.